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local relapse of lung tumor. Patient underwent lobectomy. The patient has currently a good performance status and is free of
disease.
http://dx.doi.org/10.1016/j.rpor.2013.03.149
A case of a long-survival multitreated breast cancer patient
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Breast cancer is the most common cause of cancer in women, accounting for about a third of all cancer in women. It is the most
frequently diagnosed cancer in women, primarily due to utilization of screening mammography programs. Breast cancer ranks
the second place among cancer deaths in women. In recent years, directly related to the progress of antineoplastic therapy and
earlier detection,mortality frombreast cancer has begun to decrease substantially in developed countries.We report a 81 year-old
Woman diagnosed in 1996 of a left breast neoplasia as a case of a multitreated long survivor breast cancer patient. The patient
was initially treated with lumpectomy and lymphadenectomy resulting in inﬁltrative ductal carcinoma with carcinomatous
lymphangitis and massive nodal metastasis pT4N2Mx. Completing adjuvant radiotherapy (50+20Gy) and subsequent tamoxifen
from 1996 to 2002. In 2009 bone metastases were diagnosed by scintigraphy and minimum pulmonary metastasis. Femara and
Zometa were administered. In September 2010, bone scintigraphy showed bone progression. Aromasil was prescribed. Posterior
latercervical tumor diagnosed in April 2011. Change to Faslodex. Treated with RDT (50 Gy) in November 2011 with good response.
In January 2012 CT scan evidenced multiple adenopathic tumors and two new tumor mass in right gluteus region. 4 cycles
of capecitabine were administered with secondary G3 palm-plantar disease. CT scan post-capecitabine in June 2012 showed
stable disease. In July 2012 multiple subcutaneous tumors, the biggest, in right inguinal fossa were diagnosed. Tamoxifen and
pamidronate were prescribed. In January 2013 the patient was assessed by the Radiation Oncology Department to treat right
inguinal subcutaneous bleeding tumor who ﬁnally planned 60Gy at 2Gy/fr. The radiotherapy started on 07/02/2013 with good
tolerance.
http://dx.doi.org/10.1016/j.rpor.2013.03.150
Breast cancer. A chronic disease?
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71 year old woman, previously healthy, she was diagnosed in 1992 CDI right breast, grade 1, T1 N0 M0, (AP CDI 0.5 cm grade 1
with free edges and intense intraductal component) treated with lumpectomy plus axillary clearance (18 lymph nodes without
tumor), adjuvant RT (with classical fractionation) and hormone therapy. She has continuing periodic checks in this service. In July
2009, being asymptomatic, showed elevated tumor marker CA 15.3 and was diagnosed with bone dissemination (scintigraphy:
is the pathological accumulation of radioactive material in skullcap, thoracic spine, ﬁfth left anterior rib and right scapula) PET
demonstrated an injury in D11 and, pathological uptake in the descending colon that later it was made a Colonoscopy showing
diverticula in the sigmoid. In February of 2012, was made treatment RT, in the injury, D11 DT 30Gy and with good tolerance
to the treatment. The patient started aromatase inhibitor therapy and, zoledronic acid from then until now, with good clinical.
Currently the patient is completely asymptomatic with ECOG 100%. Why this case is interesting? It is about a patient with a
20-years follow up and an active normal life, the highlights in this case are a long evolution of a breast cancer that subsequently
showed bone metastases and a demonstration of how one could have a chronic illness and still maintain a good quality of life.
http://dx.doi.org/10.1016/j.rpor.2013.03.151
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Male, 25 years old Oncological history: When he was 6 years old, after headache and vomiting episodes, a brain TC is performed
in 03/17/94 and it ﬁndings are a posterior fossa tumor with secondary hidrocephaly for which was completely surgically removed
with a PA compatible with meduloblastoma. Complicated therefrom with meningitis which left him with important neurological
sequels that improved progressively. In control cranial CT 27/06/94 nodular area is half goal in the ﬂoor of the fourth ventricle
tumor relative to rest. Oncological treatment RTE-2D with Cobalt 60 by means of two lateral ﬁelds that encompass all the craneal
volume. Simultaneously the neuroaxis is radiated by means of a direct posterior ﬁeld, with a total dose of 4.000 cGy to all
volumes with an overprint in the posterior fossa until reaching a total dose of 5.500 cGy (5×180 cGy). During the treatment, and
after presenting with neurological worsening, an IRM is performed in which it is obvious a relapse in the neuroaxis of T11-L1
which required the administration of a dose of overprinting in that area until reaching a dosage of 4.500 cGy. Tretament duration
from 08/01/94 to 09/15/94. Presented good tolerance. Evolution: He remains in follow ups persisting with neurological symptoms.
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In a 2007 radiologic follow up, two meningiomas are found (left cerebellum and right pterional región) which progressively grew
in the following years. Reason for which he was again referred to our service in February 2011 for evaluation of treatment with RT
and he was administered 54Gy at a isodose of 95% (5×200 cGy). Treatment ends July 2011. Current status Presents radiological
control of the lesions with residual neurological stability that had initially.
http://dx.doi.org/10.1016/j.rpor.2013.03.153
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Three year old, female patient. PPH: No medical or surgical background of relevance. OH: On September 1979 this patient experi-
ments progressive impotence of the right leg. During studies performed at the traumatology department in “Hospital San Rafael”
in Madrid a lithic image on the right iliac blade is discovered, an a biopsy compatible with Ewing Sarcoma is found. Another study
is performed on 04/14/1980, a bone scan, in which an intense pathological formation of activity at right iliac level is observed, and
an even higher formation is noted at the left proximal femur which could correspond to the overload caused by the adaptation
of an antalgic position. The rest of complementary studies were unremarkable. A combined chemotherapy treatment with CVA
(VCR, ADM, CPX)×2 cycles is decided upon with concurrent radiotherapy at a acurative dosage. Treatment is performed RT-2D
on right hemipelvis. 45Gy dose with subsequent overprinting on tumor volume reaching a total dose of 65Gy. Fractionation
5×200 cGy. Ending the day 20 – May-1980. Well tolerated.
Evolution. At a follow up in 1985, the tumor was under clinical control but there were some after effects to the radiotherapy
which included limited abduction and rotation of the lower right extremity and a 3.5 cm shortening of such limb that required
treatment with ALZA. And also some ﬁbrosis in the gluteal muscles where the radiation was given. In 2006 this patient was
intervened to a myomectomy with a diagnosis of uterine leiomyoma. Currently she remains symptom free (ILE 384).
http://dx.doi.org/10.1016/j.rpor.2013.03.154
Ewing sarcoma: Long-survivor
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Introduction. Ewing sarcoma is a rare tumor with an annual incidence of 2–3 cases/million habitants. It is a neuroendocrine tumor
of adolescent males more frequently located in the pelvis or long bones. Biopsy is required for diagnosis. Bad prognosis factors
are the location in the axial skeleton, adult mean age, the large tumor size and metastatic debut. It is a highly aggressive tumor
with the ability to metastasize to the lung. They are to chemotherapy and radiotherapy sensitive. The 5-year survival is 30% if
debut with metastasis.
Case. 11 year old boy who complains of pain in pelvis. In MR imaging presents 14 cm bone and soft tissue mass which inﬁltrate the
obturador muscle, contact with bladder and displace the bowel without metastases at the diagnoses. Received chemotherapy,
autologous hematopoietic stem cell (bone marrow biopsy was negative) and radical radiotherapy to the left ilium with 55.8Gy.
As toxicity he presented radiodermitis grade II with complete response. At 3 years of diagnosis presented pulmonary bilateral
progression resistant to chemotherapy. He didn’t receive radiotherapy due to previous toxicity so he was operated (pulmonary
nodules exeresis) and he received a new line chemotherapy. Currently the patient is stable with no evidence of recurrence.
Conclusions.We report a patientwith poor prognosis for high initial local aggressiveness and unresectable diseasewith pulmonary
metastases who receipt a multidisciplinary treatment with AHSC+QT+RT. The patient is stable without sings of local recurrence
or distant 5 years after diagnosis.
http://dx.doi.org/10.1016/j.rpor.2013.03.155
Gliosarcoma. A case of a long survivor
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Introduction. The gliosarcoma is the most common tumor within gliomesenquimales rare tumors. Usually settle in the temporal
lobe and affects more men.
Case report. Patient follow-up since 2005 for left mesial temporal lesion of 1.5 cm which debuted with partial seizures. Following
MRI until June 2008 when referring to morphological change observed and is derived neurosurgery treatment. Complete
tumor excision was performed and subsequent treatment with external beam radiotherapy (44–60Gy+Boost, fractionation
2Gy/day) + concomitant temozolomide (75mg/m2/day) treatment ending on 03/06/2009, subsequently received 6 cycles of
